Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16055317 | 0.81 | ERN1 (0.44) | ERN1ARKDM4EMEN1ALDH1A1 | |
| SCHEMBL16616057 | 0.80 | ERN1 (0.37) | ERN1ARMEN1ALDH1A1LMNA | |
| SCHEMBL16616115 | 0.77 | ERN1 (0.49) | ERN1ARTTRKDM4EMEN1 | |
| SCHEMBL16670446 | 0.77 | AR (0.33) | ERN1ARMEN1HPGDKMT2A | |
| SCHEMBL16670302 | 0.77 | LMNA (0.40) | ARMEN1ALDH1A1CA1CA2 | |
| SCHEMBL30646113 | 0.72 | ERN1 (0.53) | ERN1LMNA | |
| SCHEMBL28859322 | 0.69 | ERN1 (0.46) | ERN1ARKDM4EMEN1ALDH1A1 | |
| SCHEMBL31056224 | 0.68 | ERN1 (0.55) | ERN1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL16616202 | 0.68 | ERN1 (0.40) | ERN1TTRKDM4EMEN1USP2 | |
| SCHEMBL16637006 | 0.68 | TTR (0.46) | TTRKDM4EMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | ERN1 3408/4885AR 625/4885TTR 1913/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | ERN1 3034/4885AR 147/4885TTR 4308/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | ERN1 3437/4885AR 618/4885TTR 1671/4885 |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | ERN1 3448/4885AR 567/4885TTR 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.